D. E. Shaw & Co. Inc. Has $28.82 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

D. E. Shaw & Co. Inc. raised its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 240.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 666,885 shares of the company’s stock after purchasing an additional 471,111 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.71% of Scholar Rock worth $28,823,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. FMR LLC raised its position in Scholar Rock by 33.7% in the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock valued at $589,316,000 after buying an additional 3,439,215 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock valued at $127,301,000 after purchasing an additional 2,732,546 shares during the last quarter. Norges Bank bought a new position in shares of Scholar Rock during the fourth quarter valued at about $86,043,000. Adage Capital Partners GP L.L.C. purchased a new position in Scholar Rock during the fourth quarter worth about $68,930,000. Finally, Wellington Management Group LLP grew its position in Scholar Rock by 763.8% in the 4th quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company’s stock worth $74,581,000 after purchasing an additional 1,525,845 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush restated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $42.67.

Insider Activity

In other news, insider Tracey Sacco sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the sale, the insider now owns 71,750 shares of the company’s stock, valued at $2,355,552.50. The trade was a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 7,809 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the completion of the transaction, the chief financial officer now directly owns 140,740 shares of the company’s stock, valued at approximately $5,183,454.20. This trade represents a 5.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock valued at $9,220,236 in the last 90 days. Insiders own 13.30% of the company’s stock.

Scholar Rock Price Performance

Scholar Rock stock opened at $30.85 on Friday. The business’s 50 day simple moving average is $31.63 and its 200 day simple moving average is $35.87. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -13.13 and a beta of 0.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.